MetaCap

Neurogene (NGNE) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shattuck Labs (STTK) has outperformed Neurogene (NGNE) over the past year, gaining 119.7% versus a gain of 10.4%. Over five years, STTK leads with a -52.0% price change compared with -78.3% for NGNE. Neurogene is the larger company by market cap ($458.5 million vs $454.2 million), about 1.0 times the size, while Shattuck Labs is growing revenue faster (-82.5% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NGNE+10.42%STTK+119.70%
+313%+139%-34%
Nov 21, 20251 yearNov 20, 2026
NGNE-79.10%STTK-52.55%
+20%-39%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NGNE versus STTK key metrics
MetricNGNESTTK
Share price$22.15$4.46
Market cap$458.53M$454.22M
1-day change-3.40%-1.98%
YTD return+7.52%+22.19%
1-year return+10.42%+119.70%
5-year return-78.33%-51.99%
EPS (TTM)$-5.03$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$1.00M
Revenue growth (YoY)-100.00%-82.52%
Net income (latest FY)$-90.35M$-48.81M
Operating margin—-5150.80%
Net margin—-4880.90%
52-week high$43.66$8.33
52-week low$15.93$1.93
Distance from 52-week high-49.27%-46.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+250.47%+245.29%
Average volume307.78K1.20M
Shares outstanding20.70M101.84M
Employees13140
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STTK has outperformed NGNE by 109.3 percentage points over the past year.
  • Shattuck Labs grew revenue faster in its latest fiscal year (-82.52% vs -100.00%).

About Neurogene

NGNE stock →

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

NGNE vs STTK FAQ

Which is bigger, Neurogene or Shattuck Labs?

Neurogene (NGNE) is larger, with a market capitalization of $458.53M compared with $454.22M for Shattuck Labs (STTK).

Which stock has performed better over the past year, NGNE or STTK?

STTK returned +119.70% over the past 12 months, compared with +10.42% for NGNE (price return, excluding dividends). Past performance does not predict future results.

Are Neurogene and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons